Raymond James Financial
RLAY icon

Raymond James Financial’s Relay Therapeutics RLAY Stock Holding History

Raymond James Financial’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.45M Buy
346,317
+86,906
+34% +$777K ﹤0.01% 2907
2025
Q4 		$2.19M Buy
259,411
+44,588
+21% +$318K ﹤0.01% 3204
2025
Q3 		$1.12M Buy
214,823
+24,335
+13% +$92.8K ﹤0.01% 3609
2025
Q2 		$659K Buy
190,488
+5,955
+3% +$17.7K ﹤0.01% 3833
2025
Q1 		$483K Sell
184,533
-4,513
-2% -$17.7K ﹤0.01% 3957
2024
Q4 		$779K Buy
+189,046
New +$1.03M ﹤0.01% 3622

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Raymond James Financial's RLAY Position: Q1 2026 in Review

Raymond James Financial increased its Relay Therapeutics (RLAY) stake by 34% in Q1 2026, buying an estimated $777K and bringing the position to 346,317 shares worth $3.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2907.

Raymond James Financial first reported a position in RLAY in Q4 2024 and has held it in 6 quarters since. 243 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Raymond James Financial held 346,317 shares of Relay Therapeutics worth $3.45M as of Q1 2026.
  • Raymond James Financial bought 86,906 Relay Therapeutics shares in Q1 2026, an estimated $777K.
  • Relay Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #2907 holding.
  • Raymond James Financial first reported a position in Relay Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 243 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.